DuChemBIO Co.,Ltd.

176750 · KQ · Healthcare / Drug Manufacturers - Specialty & Generic

5,360.00KRW-120.00 (-2.19%)

Price History

Full chart

Market Stats

Previous Close5,480.00

Open5,510.00

Day Range5,330.00 – 5,590.00

52-Week Range5,100.00 – 12,770.00

Volume64.75K

Market Cap197.80B

P/E (TTM)0.00

Forward P/E0.00

Dividend Yield0.00%

Beta0.06

50-Day Avg6,296.00

200-Day Avg7,987.45

About

DuChemBIO Co.,Ltd. engages in the development, production, and sale of radiopharmaceutical products for cancer diagnosis and treatment in South Korea. Its products include FP-CIT for diagnosis of Parkinson's disease and Parkinson's syndrome by measuring the density of dopamine transporters present in the brain striatum; F-DOPA for brain tumor diagnosis with neutralization technology; Neuraceq for diagnosis of Alzheimer's disease by measuring the distribution and density of beta amyloid in the brain; and Vizamyl for early diagnosis of beta amyloid in Alzheimer's disease. The company also offers FES, a solution for diagnosis of metastatic breast cancer and determination of estrogen receptor status; FACBC for prostate cancer diagnosis; FDG for the diagnosis of tumors; and NaF for the diagnosis of bone-related diseases. DuChemBIO Co.,Ltd. was founded in 2002 and is based in Seoul, South Korea.

Company Details

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
CEOSang-Woo Kim
Headquarters81, Wausan-ro, Seoul, South Korea, 04041, Korea
Websitehttps://www.duchembio.com

Leadership

Sang-Woo KimChief Executive Officer

Financials

Income Statement

Currency: KRW	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	32.42B	34.70B	35.60B	38.57B
Growth (%)	-	+7.01%	+2.61%	+8.35%
Cost of Revenue	23.72B	22.90B	23.37B	24.34B
Gross Profit	8.70B	11.80B	12.23B	14.23B
Gross Margin	26.83%	34.00%	34.36%	36.89%
Operating Expense	7.14B	6.54B	7.16B	6.79B
Operating Income	1.56B	5.26B	5.08B	7.44B
Operating Margin	4.80%	15.15%	14.26%	19.30%
EBITDA	6.11B	11.18B	12.22B	14.59B
EBITDA Margin	18.85%	32.21%	34.33%	37.82%
Net Income	-2.60B	4.00B	7.99B	6.48B
Net Income Margin	-8.02%	11.53%	22.45%	16.80%
R&D	17.52M	205.31M	-	22.57M
R&D as % of Total Revenue	0.05%	0.59%	-	0.06%
Interest Expense	1.51B	1.36B	1.09B	1.06B
Interest Expense % of Total Revenue	4.66%	3.93%	3.06%	2.75%

Balance Sheet

Currency: KRW	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	51.35B	49.28B	65.17B	77.68B
Total Liabilities	33.76B	27.48B	22.16B	28.44B
Total Equity	17.59B	21.79B	43.01B	49.24B
Cash	2.59B	1.97B	10.69B	15.45B
Net Debt	16.09B	11.41B	-	-

Cash Flow

Currency: KRW	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	8.24B	8.44B	7.03B	9.94B
Capital Expenditure	730.54M	1.30B	1.87B	877.82M
Free Cash Flow	7.51B	7.14B	5.16B	9.06B
FCF to OCF	91.13%	84.63%	73.36%	91.17%

Earnings

Report Date	Dec 31, 2024	Mar 31, 2025	Jun 30, 2025	Sep 30, 2025	Dec 31, 2025	Mar 31, 2026	Jun 30, 2026
EPS Estimate	-	-	-	-	-	-	-
EPS Actual	169.88	13.33	47.71	50.49	116.69	30.78	42.43
Surprise	-	-	-	-	-	-	-
Timing	-	-	-	-	-	-	-

Key Statistics & Ratios

Market Cap197.80B

Enterprise Value179.65B

Trailing P/E0.00

Forward P/E0.00

Price / Sales4.77

Price / Book3.45

Revenue (TTM)41.51B

Gross Profit (TTM)15.70B

EBITDA16.80B

Profit Margin16.45%

Operating Margin17.25%

Return on Equity14.17%

Return on Assets6.98%

Shares Outstanding28.38M

Shares Float11.05M

Beta0.06

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%